Lyell Immunopharma, Inc. (LYEL) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Market Cap | 526.12M |
| Enterprise Value | 516.94M |
| P/E Ratio | -0.59 |
| PEG Ratio | 0 |
| Price/Sales Ratio | 8,540.22 |
| Price/Book Ratio | 0.94 |
| Enterprise/Revenue | 7,205 |
| Enterprise/EBITDA | -0.81 |
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | June 30, 2026 |
| Profit Margin | -9,202.85 |
| Operating Margin | -7,113.3 |
| Return On Assets | -0.8 |
| Return On Equity | -0.92 |
| Revenue | 36,000 |
| Revenue/Share | 0 |
| Gross Profit | -11.5M |
| EBITDA | -262.91M |
| Net Income | -274.45M |
| Diluted EPS | -16.06 |
| Total Cash | 204.1M |
| Total Cash/Share | 8.74 |
| Total Debt | 36.93M |
| Total Debt/Equity | 0.16 |
| Current Ratio | 5.36 |
| Book Value Per Share | 10.01 |
| 52-Week Change | -40.48 |
| 52-Week High | 45 |
| 52-Week Low | 9.36 |
| Moving Average 50 Days | 13 |
| Moving Average 200 Days | 19.09 |
| Average Volume | 150,428 |
| Shares Outstanding | 24.5M |
| % Held by Institutions | 51.75 |
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
| Last Split Date | June 02, 2025 |